Chiusura precedente | 6,83 |
Aperto | 6,90 |
Denaro | 4,83 x 200 |
Lettera | 8,80 x 200 |
Min-Max giorno | 6,66 - 6,90 |
Intervallo di 52 settimane | 5,10 - 19,35 |
Volume | |
Media Volume | 21.546 |
Capitalizzazione | 19,18M |
Beta (5 anni mensile) | -1,84 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -17,35 |
Prossima data utili | 07 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 19,33 |
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 1,910 shares of its common stock to one new employee. The stock options were granted on September 15, 2023. The grant
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED ---- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases ---- As of June 30, 2023, $59.2 mi